A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors

Eisai Inc.0 sites55 target enrollmentJune 22, 2008

ConditionsAdvanced Solid Tumors

InterventionsE6201

DrugsE6201

Overview

Phase: Phase 1
Intervention: E6201
Conditions: Advanced Solid Tumors
Sponsor: Eisai Inc.
Enrollment: 55
Primary Endpoint: Maximum tolerated dose and dose-limiting toxicities as determined in Part A.
Status: Completed
Last Updated: 3 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Similar Trials

Overview

Brief Summary

The purpose of this study is to determine the maximum tolerated dose (MTD), safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of E6201 in subjects with advanced solid tumors.

Registry

clinicaltrials.gov

Start Date

June 22, 2008

End Date

October 15, 2015

Last Updated

3 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Eisai Inc.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Subjects must meet all of the following criteria to be eligible to participate in this study:
•Willing and able to comply with the protocol and provide written informed consent.
•Age greater than or equal to 18 years.
•Histologically and/or cytologically confirmed metastatic melanoma which has progressed after treatment with approved therapies or for which there are no standard effective therapies available. CNS metastases from a primary melanoma are allowed.
•Subjects must have melanoma tumor status established by a BRAF-gene analysis report from a CLIA qualified laboratory.
•Subjects must have at least one tumor lesion accessible to biopsy in addition to one which is accurately and serially measurable according to RECIST 1.0 using either CT/MRI or photography (as appropriate), and which measures greater than 1.5 cm in the longest diameter for a non-lymph node and greater than 2.0 cm in the short axis diameter for a lymph node.
•Female subjects of childbearing potential must agree to use medically acceptable methods of contraception, such as abstinence, double-barrier method (e.g., condom and spermicide; condom, diaphragm, and spermicide), intrauterine device (IUD), or have a vasectomised partner. Female subjects who use hormonal contraceptives must also use an additional approved method of contraception (as described previously). Contraceptive measures must start either prior to or at Screening and continue throughout the entire study period and for 2 months after the last dose drug is administered. Pregnant and/or lactating females are excluded.
•Male subjects must agree to use contraceptive methods such as abstinence, or double-barrier method (e.g., condom and spermicide; condom, diaphragm, and spermicide). Contraceptive measures must start either prior to or at Screening and continue throughout the entire study period and for 2 months after the last dose of study drug is administered.
•Adequate bone marrow function defined as:
•Absolute neutrophil count (ANC) greater than or equal to 1.5 x 10\^9/L

Exclusion Criteria

•Subjects who meet any of the following criteria are not eligible to participate in this study:
•Known human immunodeficiency virus (HIV), clinical evidence of active viral hepatitis B or C, or severe/uncontrolled infections or intercurrent illness that is unrelated to the tumor.
•Prior surgery, radiotherapy, chemotherapy, biologic therapy, or investigational agents within 4 weeks prior to the first infusion and prior immunotherapy, hormonal, or molecular-targeted therapy within 2 weeks prior to the first infusion. All acute toxicities related to prior treatments should have resolved.
•Active malignancy other than the present diagnosis within the past 24 months (except treated non-melanoma skin cancer or carcinoma in situ of the cervix).
•QT interval corrected for rate (QTc) greater than 450 msec on the electrocardiogram (ECG) obtained at Screening (Day -21 to 0) using the Fridericia method for QTc analysis.
•History or substance or alcohol abuse which, in the opinion of the investigator, would prohibit participation in the study.
•History of clinically significant cardiac impairment, congestive heart failure, New York Heart Association (NYHA) cardiac disease classification Class II, unstable angina, or myocardial infarction during the previous 6 months, or serious cardiac arrhythmia.
•Current significant co-morbid disease which, in the opinion of the investigator, would exclude the subject from the study.

Arms & Interventions

1

Intervention: E6201

Outcomes

Primary Outcomes

Maximum tolerated dose and dose-limiting toxicities as determined in Part A.

Time Frame: During Cycle 1: 28 days

Safety parameters (adverse events, laboratory data, vital signs, electrocardiogram data, Eastern Cooperative Oncology Group [ECOG] scores, and physical and neurological exams).

Time Frame: During Parts A and B: approximately 26 months

Secondary Outcomes

Pharmacokinetics(Obtained prior to infusion on Day 1 of Cycle 1 (Baseline), during the infusion at 15 and 30 minutes (just prior to end of infusion), then after the end of infusion at 5 and 30 minutes, and 1, 2, 4, 8, 24, and 48 hours on Days 1 and 15 of Cycle 1 only.)
Pharmacodynamics(Prior to and post-infusion at timepoints between Days 1 and 15, and on Day 1 of Cycle 2)
Preliminary efficacy: Tumor assessments of objective response rate based on review of computed tomography and magnetic resonance imaging scans using Modified Response Evaluation Criteria in Solid Tumors.(Performed at baseline and every other cycle.)